Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals

Published 02 Oct 2026, 11:23 UTC. Updated 06 Oct 2026, 14:07 UTC.

Western biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer.

Directly affected

No company is named in this report.

Indirectly affected

CPHI CHINA PHARMA HLDGS INC
GA selected CPHI as a RELATED security because its canonical security name directly matches this event's themes: pharma, china. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.

Price reaction, T-5 to T+3

Ticker	T-5	T-3	T-1	T0	T+1	T+2	T+3
CPHI	—	—	—	—	—	—	—
ACHC	—	—	—	—	—	—	—
ASND	—	—	—	—	—	—	—
ATYR	—	—	—	—	—	—	—
BBIO	—	—	—	—	—	—	—
DVA	—	—	—	—	—	—	—

Western biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer.

Source: CNBC Top

The price since 2 Oct 2026: China Pharma Holdings (CPHI) versus the S&P 500

Since the first closing price after “Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals,” China Pharma Holdings (CPHI) is +2.49%. The S&P 500 fund (SPY) is -1.08% over the same days, a +3.57% difference versus the market.

CPHI

SPY

Filings that name China Pharma Holdings (CPHI) around 2 Oct 2026

Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). That is 3 days before publication, inside 30 days. The filing is listed beside the story “Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals.”

Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).

Who gains and who loses around China Pharma Holdings (CPHI)

Companies mentioned with this story

CPHI China Pharma Holdings
In “Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals,” China Pharma Holdings (CPHI) is linked, with no stored direction, medium confidence. Reason on file: GA selected CPHI as a RELATED security because its canonical security name directly matches this event's themes: pharma, china. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
ACHC Acadia Healthcare
In “Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals,” Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
ASND Ascendis Pharma A/S
For “Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals,” Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence. Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
ATYR aTYR PHARMA
In “Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals,” aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence. Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
BBIO BridgeBio Pharma
For “Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
DVA Davita
For “Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals,” Davita (DVA) is linked, with no stored direction, medium confidence. Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article

China Pharma Holdings (CPHI)

“Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals” (2 Oct 2026) reaches China Pharma Holdings (CPHI) through this story.

The link for China Pharma Holdings (CPHI) is this: GA selected CPHI as a RELATED security because its canonical security name directly matches this event's themes: pharma, china. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article

Also listed, Acadia Healthcare (ACHC): GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article

The price range for China Pharma Holdings (CPHI), and the dates in the story

ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. CPHI traded between 0.64 and 1.28 across 20 sessions. The latest close on file is 0.67.

A simple score for China Pharma Holdings (CPHI)

46 out of 100

“Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.